{"doi":"10.1183/13993003.00930-2025","title":"Hypoxic markers of severity and precision predictive outcomes in paediatric obstructive sleep apnoea: the quest must go on!","abstract":"<title>Extract</title> Paediatric sleep disordered breathing (SDB) is a frequent and highly prevalent condition whose clinical relevance has continued to accrue in light of the potential morbid consequences that can result from leaving the condition untreated [1, 2]. The spectrum of the disease includes, at one end, children with habitual snoring without any evidence of gas exchange abnormalities and altered sleep architecture (also termed primary snoring), while at its other end, it will manifest as very frequent obstructive events (<italic>i.e.</italic> apnoea or hypopnoea) accompanied by significant intermittent hypoxaemia and hypercapnia coupled with recurrent arousals leading to substantial sleep fragmentation (obstructive sleep apnoea (OSA)) [3]. In this context, the field has uncovered <italic>a priori</italic> contradictory features that have thus far precluded a firm delineation of the individual risk for the presence of any given end-organ morbidity: 1) there are children with clear polysomnographic evidence of OSA who are completely free from any morbid consequences, while there are children with primary snoring who are obviously symptomatic and manifest cognitive or cardiovascular dysfunction [4–7]; and 2) a dose-dependent effect of OSA severity has been identified whereby the probability of cognitive deficits and possibly systemic hypertension increases as the severity of OSA increases [8–10].","journal":"European Respiratory Journal","year":2025,"id":545908,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9725,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":278385,"name":"David Gozal","orcid":"0000-0001-8195-6036","position":0,"is_corresponding":true}],"reference_count":35,"raw_metadata":null,"created_at":"2026-07-19T02:53:27.751050Z","pmid":"40780853","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}